Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study.
OBJECTIVE
This study evaluated the efficacy and safety of adjuvant chemotherapy with the docetaxel plus cisplatin and 5-fluorouracil (5-FU) (DCF) regimen in patients with gastric cancer.


METHODS
Thirty-two patients with gastric or gastroesophageal junction cancer were enrolled in this study after undergoing radical resection. The patients received the following chemotherapy: docetaxel (60 mg/m(2)) on day 1, cisplatin (12 mg/m(2) per day) on days 1 to 5, and 5-FU (2500 mg/m(2)) continuous infusion for 120 hours, repeated every 3 weeks for six cycles. The primary end point was disease-free survival (DFS).


RESULTS
The median DFS was 17.0 months. The 1-year DFS was 72%, and the 2-year DFS was 37.5%. The median overall survival was 28.0 months. Using univariate analysis, the technique of lymph node dissection was a predictor for postoperative relapse. The median DFS was 15.0 months in the D1 group and 18.0 months in the D2 group (P = .043). The most frequent grade 3/4 adverse events were neutropenia (56.25%), diarrhea (9.38%), nausea (6.25%), and vomiting (6.25%); 12.5% of patients developed febrile neutropenia. There were no chemotherapy-related deaths.


CONCLUSIONS
The modified DCF regimen is an effective adjuvant chemotherapy in gastric cancer. Hematologic toxicity was frequent but manageable. This regimen merits further investigation.
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Changting
C
Meng
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Hongyan
H
Yin
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zhao
Z
Sun
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Jianfeng
J
Zhou
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Shuchang
S
Chen
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Chunmei
C
Bai
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. Electronic address: wz20010727@aliyun.com.
Lin
L
Zhao